MorphoSys’ Antibodies by Design and Chimera Biotec Announce Cooperation and Co-Marketing Agreement
20 February 2006
Antibodies by Design, a Division of MorphoSys AG, Munich, and Chimera Biotec GmbH today announced the start of a co-marketing agreement between the two companies. Within the scope of the agreement the parties agree to co-market the rapid generation of monoclonal antibodies by Antibodies by Design and Chimera Biotec’s complementary Imperacer™ assay technology for ultra-sensitive antigen detection. Each partner will offer the services of the other to its customers throughout the world-wide market.
To view the complete customer update please visit our webpage.
